Michael Hallek to Humans
This is a "connection" page, showing publications Michael Hallek has written about Humans.
Connection Strength
0.262
-
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 11; 19(11):715-722.e6.
Score: 0.007
-
How to approach CLL in clinical practice. Hematol Oncol. 2019 Jun; 37 Suppl 1:38-42.
Score: 0.007
-
Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials. Anticancer Res. 2019 May; 39(5):2591-2598.
Score: 0.007
-
New roles for B cell receptor associated kinases: when the B cell is not the target. Leukemia. 2019 03; 33(3):576-587.
Score: 0.006
-
Early Palliative Care: Pro, but Please Be Precise! Oncol Res Treat. 2019; 42(1-2):11-18.
Score: 0.006
-
[Multiple myeloma]. Internist (Berl). 2019 01; 60(1):1-2.
Score: 0.006
-
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019 05; 33(5):1161-1172.
Score: 0.006
-
On the architecture of translational research designed to control chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):1-8.
Score: 0.006
-
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther. 2018; 12:2577-2590.
Score: 0.006
-
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 09; 19(9):1215-1228.
Score: 0.006
-
Venetoclax after idelalisib: relevant progress for CLL. Blood. 2018 04 12; 131(15):1632-1633.
Score: 0.006
-
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 06 21; 131(25):2745-2760.
Score: 0.006
-
[Diagnostic management of fever]. Internist (Berl). 2018 Mar; 59(3):218-226.
Score: 0.006
-
[Which drugs in Hemato-Oncology are Unnecessary or Inappropriate for Use in the Elderly?] Dtsch Med Wochenschr. 2018 02; 143(4):244-252.
Score: 0.006
-
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018 Mar; 14(6):499-513.
Score: 0.006
-
Chronic lymphocytic leukaemia. Lancet. 2018 04 14; 391(10129):1524-1537.
Score: 0.006
-
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018 03 01; 131(9):955-962.
Score: 0.006
-
Optimizing frontline therapy of CLL based on clinical and biological factors. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):338-345.
Score: 0.006
-
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct; 4(10):e475-e486.
Score: 0.006
-
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017 Sep; 92(9):946-965.
Score: 0.006
-
Role and timing of new drugs in CLL. Hematol Oncol. 2017 Jun; 35 Suppl 1:30-32.
Score: 0.006
-
Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 05 11; 129(19):2702-2705.
Score: 0.006
-
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14; 127(2):208-15.
Score: 0.005
-
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol. 2015; 11(1):51-9.
Score: 0.005
-
[Elderly patients in clinical trials: new fitness-adapted concepts]. Internist (Berl). 2007 Nov; 48(11):1232-7.
Score: 0.003
-
Report on the 1st international workshop of the german competence network malignant lymphomas. Onkologie. 2007 May; 30(5):265-73.
Score: 0.003
-
Providing care in isolation while awaiting SARS-CoV-2 test results: Considering differential diagnoses and avoiding anchoring bias. Medicine (Baltimore). 2021 Jul 30; 100(30):e26720.
Score: 0.002
-
Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19. EMBO Mol Med. 2021 08 09; 13(8):e14150.
Score: 0.002
-
[Development of vaccines for prevention of COVID-19: part 3]. Internist (Berl). 2021 Jun; 62(6):690-693.
Score: 0.002
-
[Antibody therapy in patients with COVID-19]. Internist (Berl). 2021 May; 62(5):572-576.
Score: 0.002
-
[Development of vaccines for prevention of COVID-19: part 2]. Internist (Berl). 2021 Mar; 62(3):337-340.
Score: 0.002
-
[Development of vaccines for prevention of COVID-19]. Internist (Berl). 2021 Jan; 62(1):106-110.
Score: 0.002
-
[Morphological and molecular changes in the lung of COVID-19 patients]. Internist (Berl). 2020 Dec; 61(12):1304-1307.
Score: 0.002
-
Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia. Bone Marrow Transplant. 2021 03; 56(3):716-719.
Score: 0.002
-
[Remdesivir for patients with COVID-19]. Internist (Berl). 2020 Aug; 61(8):869-872.
Score: 0.002
-
COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia. Eur J Haematol. 2020 Oct; 105(4):508-511.
Score: 0.002
-
COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. 2020 08; 34(8):2225-2229.
Score: 0.002
-
[Remdesivir for patients with severe COVID-19]. Internist (Berl). 2020 Jun; 61(6):644-645.
Score: 0.002
-
COVID-19 associated pulmonary aspergillosis. Mycoses. 2020 Jun; 63(6):528-534.
Score: 0.002
-
Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020. Euro Surveill. 2020 05; 25(21).
Score: 0.002
-
Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica. 2019 11; 104(11):2144-2154.
Score: 0.002
-
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica. 2020 05; 105(5):1379-1390.
Score: 0.002
-
Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53. Theranostics. 2019; 9(21):6047-6062.
Score: 0.002
-
Characteristics and course of patients with advanced hematologic malignancies receiving specialized inpatient palliative care at a German university hospital. Ann Hematol. 2019 Nov; 98(11):2605-2607.
Score: 0.002
-
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402.
Score: 0.002
-
Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica. 2019 09; 104(9):1798-1803.
Score: 0.002
-
HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation? Infection. 2019 Apr; 47(2):293-300.
Score: 0.002
-
Management of unfit elderly patients with chronic lymphocytic leukemia. Eur J Intern Med. 2018 12; 58:7-13.
Score: 0.002
-
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br J Haematol. 2018 12; 183(5):727-735.
Score: 0.002
-
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma. 2019 06; 60(6):1438-1446.
Score: 0.002
-
Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence. Sci Rep. 2018 10 08; 8(1):14941.
Score: 0.002
-
[The 2017/2018 influenza season-business as usual? : A statement of medical societies]. Internist (Berl). 2018 Oct; 59(10):1122-1124.
Score: 0.002
-
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. Leuk Lymphoma. 2019 03; 60(3):649-657.
Score: 0.002
-
[Individualized Treatment of Chronic Lymphocytic Leukemia (CLL)]. Dtsch Med Wochenschr. 2018 09; 143(18):1318-1324.
Score: 0.002
-
Der ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis. Oncol Res Treat. 2018; 41 Suppl 3:2-26.
Score: 0.002
-
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018 10; 37(42):5682-5693.
Score: 0.002
-
Effects of Kyusho Jitsu on Physical Activity-levels and Quality of Life in Breast Cancer Patients. In Vivo. 2018 Jul-Aug; 32(4):819-824.
Score: 0.002
-
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018 09 15; 24(18):4371-4379.
Score: 0.002
-
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 07 01; 36(19):1973-1980.
Score: 0.002
-
Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018 04 16; 11(1):55.
Score: 0.002
-
Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. Biomed Res Int. 2018; 2018:1023490.
Score: 0.002
-
[Profit center analysis of esophagectomy : Economical analysis of transthoracic esophagectomy depending on postoperative complications]. Chirurg. 2018 03; 89(3):229-236.
Score: 0.002
-
Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review. Breast Cancer Res Treat. 2018 Jul; 170(1):1-13.
Score: 0.002
-
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018 02 20; 9(1):727.
Score: 0.002
-
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018 02 15; 9(1):697.
Score: 0.002
-
The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies - STOP. BMC Cancer. 2018 01 10; 18(1):62.
Score: 0.002
-
Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2018 03; 53(3):255-263.
Score: 0.001
-
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. Leuk Lymphoma. 2018 07; 59(7):1614-1623.
Score: 0.001
-
Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia. Blood. 2017 11 30; 130(22):2443-2444.
Score: 0.001
-
On Taking a Different Route: An Unlikely Case of Malaria by Nosocomial Transmission. Clin Infect Dis. 2017 10 15; 65(8):1404-1406.
Score: 0.001
-
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int J Cancer. 2018 01 15; 142(2):322-333.
Score: 0.001
-
[Priorities of German Oncologists. Results of the "choosing wisely" survey of the German Society of Hematology and Medical Oncology (DGHO)]. Dtsch Med Wochenschr. 2017 Sep; 142(18):e124-e130.
Score: 0.001
-
Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016. Euro Surveill. 2017 Sep; 22(39).
Score: 0.001
-
Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia. 2018 02; 32(2):364-375.
Score: 0.001
-
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017 12; 31(12):2833-2837.
Score: 0.001
-
Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy. Cancer Immunol Res. 2017 09; 5(9):730-743.
Score: 0.001
-
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nat Commun. 2017 07 28; 8(1):153.
Score: 0.001
-
Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia. Leukemia. 2017 10; 31(10):2271-2273.
Score: 0.001
-
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 09 21; 130(12):1477-1480.
Score: 0.001
-
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia. 2017 10; 31(10):2251-2253.
Score: 0.001
-
Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia. 2017 10; 31(10):2244-2247.
Score: 0.001
-
[Response to and further development of the Choosing wisely initiative]. Internist (Berl). 2017 Jun; 58(6):527-531.
Score: 0.001
-
[Choosing Wisely-evidence-based]. Internist (Berl). 2017 06; 58(6):525-526.
Score: 0.001
-
Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-?B signaling. Leukemia. 2018 01; 32(1):72-82.
Score: 0.001
-
Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue. Br J Haematol. 2017 09; 178(6):949-953.
Score: 0.001
-
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clin Cancer Res. 2017 Sep 01; 23(17):5292-5301.
Score: 0.001
-
Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. Lung Cancer. 2017 06; 108:134-139.
Score: 0.001
-
Targeting of B-cell receptor signalling in B-cell malignancies. J Intern Med. 2017 11; 282(5):415-428.
Score: 0.001
-
Defects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: relationship to disease progression. Eur J Clin Invest. 1997 Feb; 27(2):121-7.
Score: 0.001
-
A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br J Cancer. 2017 Feb 28; 116(5):600-608.
Score: 0.001
-
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Des Devel Ther. 2017; 11:295-304.
Score: 0.001
-
Recombinant adeno-associated virus (rAAV) vectors for somatic gene therapy: recent advances and potential clinical applications. Cytokines Mol Ther. 1996 Jun; 2(2):69-79.
Score: 0.001
-
Emerging therapies for refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Feb; 56(2):285-92.
Score: 0.001
-
Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 09; 367(6):520-31.
Score: 0.001
-
Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol. 1992 Jul; 65(1):1-5.
Score: 0.001
-
Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology. 2011 Jan 05; 409(1):77-83.
Score: 0.001
-
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009 Sep 24; 114(13):2589-97.
Score: 0.001
-
Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma. 2008 Dec; 49(12):2256-62.
Score: 0.001
-
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol. 2007 Jan; 136(1):63-72.
Score: 0.001